Heidelberg Pharma AG (LTS:0QW5) Interest Expense : €-0.24 Mil (TTM As of Aug. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Heidelberg Pharma AG's interest expense for the three months ended in Aug. 2024 was € -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Aug. 2024 was €-0.24 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Heidelberg Pharma AG's Operating Income for the three months ended in Aug. 2024 was € -6.11 Mil. Heidelberg Pharma AG's Interest Expense for the three months ended in Aug. 2024 was € -0.00 Mil. Heidelberg Pharma AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Heidelberg Pharma AG Interest Expense Historical Data

The historical data trend for Heidelberg Pharma AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Interest Expense Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.49

-0.84

-0.76

Heidelberg Pharma AG Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Interest Expense	Get a 7-Day Free Trial															-0.16	-0.10	-0.10	-0.04	-

Heidelberg Pharma AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.24 Mil.

Heidelberg Pharma AG (LTS:0QW5) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Heidelberg Pharma AG's Interest Expense for the three months ended in Aug. 2024 was €-0.00 Mil. Its Operating Income for the three months ended in Aug. 2024 was €-6.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Aug. 2024 was €0.04 Mil.

Heidelberg Pharma AG's Interest Coverage for the quarter that ended in Aug. 2024 is calculated as

Heidelberg Pharma AG did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines